BMRA
BEARISH
$2.57
Live
Biomerica, Inc. · NASDAQ
$2.11
52W Range
$8.8
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$7.76M
P/E
N/A
ROE
-84.3%
Profit margin
-90.3%
Debt/Equity
0.06
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
The Advanced Deterministic Scorecard reveals severe financial distress with a Piotroski F-Score of just 1/9, indicating extremely weak fundamental health. Despite a seemingly healthy Current Ratio of 3.25 and low Debt/Equity of 0.06, the company is plagued by deep profitability issues, including a -90.31% profit margin and -84.30% ROE. Revenue has declined by 26% year-over-year, and the stock has lost 95.7% of its value over five years, reflecting persistent operational failures and lack of investor confidence. The absence of an Altman Z-Score due to incomplete data further limits confidence in solvency assessments, but the overwhelming negative trends in earnings, margins, and price performance dominate the outlook.
Key Strengths
Low Debt/Equity ratio of 0.06 suggests minimal leverage risk
Current Ratio of 3.25 indicates strong short-term liquidity
Quick Ratio of 2.18 supports near-term financial flexibility
Forward P/E of 6.59 appears low relative to sector average of 215, suggesting potential value if turnaround occurs
Gross margin, though thin, remains positive at 5.63%
Key Risks
Piotroski F-Score of 1/9 signals critical weakness in earnings, leverage, and operating efficiency
Profit margin of -90.31% and operating margin of -113.47% reflect severe unprofitability
Revenue growth down 26% YoY, indicating shrinking top line and possible market rejection
History of massive earnings misses: average surprise of -256.34% over last 4 quarters
Stock down 95.7% over 5 years with no analyst coverage, signaling abandonment by institutional interest
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
12
Weak
35
10
8
6
0
AI Verdict
Extremely high-risk investment with deteriorating fundamentals and no catalysts for recovery
Key drivers: Piotroski F-Score of 1/9, Consistent earnings misses and negative margins, Catastrophic long-term price performance, Absence of analyst coverage and intrinsic value metrics
Confidence
96%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Low Forward P/E of 6.59 may suggest undervaluation
- Price/Book of 1.71 below many speculative peers
Watchpoints
- No Graham Number or Intrinsic Value available
- Negative earnings invalidate P/E interpretation
- P/B and P/S ratios meaningless given unprofitability
Future
10/100
Ref Growth rates
Positives
- Forward P/E implies some expectation of future profitability
Watchpoints
- Revenue growth declining at -26% YoY
- No earnings growth data available due to losses
- No evidence of improving trends in guidance or estimates
Past
8/100
Ref Historical trends
Positives
No standout positives identified.
Watchpoints
- 5-year return of -95.7% shows near-total value erosion
- 25 consecutive quarters of earnings volatility and misses
- Long history of negative EPS surprises, including -700% miss
Health
6/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current and Quick Ratios above industry norms
- Very low Debt/Equity ratio
Watchpoints
- Piotroski F-Score of 1/9 indicates critical financial weakness
- No Altman Z-Score due to missing data, increasing uncertainty
- ROE of -84.30% and ROA of -49.44% show capital destruction
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- Dividend Strength score of 0/100
- Payout ratio of 0% due to lack of dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.57
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BMRA and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BMRA
Biomerica, Inc.
Primary
|
-95.7% | -88.5% | -46.5% | -34.3% | -3.0% | 0.0% |
|
ALUR
Allurion Technologies Inc.
Peer
|
-99.8% | -99.8% | -84.6% | -75.5% | -69.7% | -11.7% |
|
ZCMD
Zhongchao Inc.
Peer
|
-98.6% | -97.8% | -76.2% | -65.0% | +13.5% | -2.1% |
|
EVGN
Evogene Ltd.
Peer
|
-98.3% | -86.8% | -23.5% | -45.0% | +5.7% | -0.8% |
|
IMRN
Immuron Limited
Peer
|
-85.9% | -59.6% | -51.9% | -61.7% | -3.3% | -1.0% |
BMR
Biomerica, Inc.
Primary
5Y
-95.7%
3Y
-88.5%
1Y
-46.5%
6M
-34.3%
1M
-3.0%
1W
0.0%
ALU
Allurion Technologies Inc.
Peer
5Y
-99.8%
3Y
-99.8%
1Y
-84.6%
6M
-75.5%
1M
-69.7%
1W
-11.7%
ZCM
Zhongchao Inc.
Peer
5Y
-98.6%
3Y
-97.8%
1Y
-76.2%
6M
-65.0%
1M
+13.5%
1W
-2.1%
EVG
Evogene Ltd.
Peer
5Y
-98.3%
3Y
-86.8%
1Y
-23.5%
6M
-45.0%
1M
+5.7%
1W
-0.8%
IMR
Immuron Limited
Peer
5Y
-85.9%
3Y
-59.6%
1Y
-51.9%
6M
-61.7%
1M
-3.3%
1W
-1.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
6.59
PEG Ratio
N/A
P/B Ratio
1.71
P/S Ratio
1.74
EV/Revenue
1.24
EV/EBITDA
-1.06
Market Cap
$7.76M
Profitability
Profit margins and return metrics
Profit Margin
-90.31%
Operating Margin
-113.47%
Gross Margin
5.63%
ROE
-84.3%
ROA
-49.44%
Growth
Revenue and earnings growth rates
Revenue Growth
-26.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.06
Low debt
Current Ratio
3.25
Strong
Quick Ratio
2.18
Excellent
Cash/Share
$0.84
Quarterly Earnings History
EPS performance vs analyst estimates
2023-04-14
$-0.96
-700.0% surprise
2022-01-12
$-0.72
-12.5% surprise
2021-10-14
$-0.96
2021-08-27
$-0.96
-56.5% surprise
Healthcare Sector Comparison
Comparing BMRA against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-84.3%
This Stock
vs
-88.14%
Sector Avg
-4.4%
(Below Avg)
Profit Margin
-90.31%
This Stock
vs
-16.28%
Sector Avg
+454.7%
(Superior)
Debt to Equity
0.06
This Stock
vs
2.66
Sector Avg
-97.6%
(Less Debt)
Revenue Growth
-26.0%
This Stock
vs
124.04%
Sector Avg
-121.0%
(Slower)
Current Ratio
3.25
This Stock
vs
4.47
Sector Avg
-27.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BMRA
Biomerica, Inc.
|
BEARISH | $7.76M | - | -84.3% | -90.3% | $2.57 | |
|
ALUR
Allurion Technologies Inc.
|
BEARISH | $7.92M | - | -% | -187.9% | $0.53 | Compare |
|
ZCMD
Zhongchao Inc.
|
BEARISH | $7.92M | - | -24.9% | -55.5% | $2.06 | Compare |
|
EVGN
Evogene Ltd.
|
BEARISH | $7.95M | - | -100.7% | -220.2% | $0.8 | Compare |
|
IMRN
Immuron Limited
|
BEARISH | $8.1M | - | -39.7% | -62.1% | $0.79 | Compare |
BMRA
Biomerica, Inc.
BEARISH
Mkt Cap
$8M
P/E
-
ROE
-84.3%
Price
$2.57
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-12 | IRANI ZACKARY S | Chief Executive Officer | Stock Award | 52,500 | - |
| 2025-12-12 | BARBIERI ALLEN | Officer and Director | Stock Award | 30,000 | - |
| 2025-12-12 | MOATAZEDI DAVID | Director | Stock Award | 20,000 | - |
| 2025-12-12 | HUFF GARY M | Director | Stock Award | 20,000 | - |
| 2025-12-12 | LU GARY | Chief Financial Officer | Stock Award | 40,000 | - |
IRANI ZACKARY S
Chief Executive Officer
2025-12-12
52,500 shares
BARBIERI ALLEN
Officer and Director
2025-12-12
30,000 shares
MOATAZEDI DAVID
Director
2025-12-12
20,000 shares
HUFF GARY M
Director
2025-12-12
20,000 shares
LU GARY
Chief Financial Officer
2025-12-12
40,000 shares
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning BMRA from our newsroom.
Newest → oldest
No matching news yet.